Prevalence and clinical characteristics of patients with brain metastases at diagnosis with advanced hepatocellular carcinoma in a retrospective registry. Concurrent transarterial chemoembolization ...

Addition of the anti-TIGIT monoclonal antibody tiragolumab to standard first-line treatment resulted in better response rates ...

A multicenter, prospective observational study of chemotherapy in elderly patients with biliary tract cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium.

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.

Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683 Technology appraisal guidance Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162] ...

Casdozokitug, combined with atezolizumab and bevacizumab, shows durable responses and a 17.2% complete response rate in HCC ...